Benzinga | Sep 14, 2021 07:36AM EDT

Oppenheimer Maintains Outperform on aTyr Pharma, Raises Price Target to $20

Oppenheimer analyst Hartaj Singh maintains aTyr Pharma (NASDAQ:LIFE) with a Outperform and raises the price target from $14 to $20.